CogState Ltd is primarily active in the healthcare and pharmaceutical industries.

The main competitors of CogState Ltd in the market are Cambridge Cognition Holdings PLC, Neurotrack Technologies Inc., and CogniFit Ltd. These companies also specialize in cognitive assessment and provide similar solutions and services. However, CogState Ltd distinguishes itself through its innovative technologies and partnerships, including collaborations with leading pharmaceutical companies. With its strong focus on enhancing the understanding and measurement of cognitive function, CogState Ltd continues to remain competitive in the market and deliver valuable solutions to its clients.

CogState Ltd is a renowned company with a rich history and background. Founded in 1999, CogState specializes in cognitive testing and offers innovative solutions to improve brain health assessment. With its headquarters in Melbourne, Australia, the company has expanded its global presence, serving various sectors including pharmaceuticals, biotechnology, and academic research. CogState has developed cutting-edge technologies and software platforms to deliver accurate and efficient cognitive assessments, benefiting patients, researchers, and professionals worldwide. Known for its advanced cognitive testing methods and commitment to enhancing brain health, CogState Ltd has established itself as a trusted industry leader.

CogState Ltd has achieved several significant milestones in its history. One key achievement is the development and commercialization of its pioneering cognitive testing technology, known as the CogState Computerized Cognitive Assessment Tool (CCAT). This innovative tool is widely utilized in clinical trials and research studies worldwide, enabling precise and objective measurement of cognitive function. Additionally, CogState Ltd has successfully established strategic partnerships with leading pharmaceutical companies, academic institutions, and healthcare providers, facilitating the widespread adoption of its solutions. The company continues to thrive through ongoing research and development, further cementing its position as a global leader in cognitive assessment technology.

CogState Ltd is primarily present in Australia, the United States, and Europe.

CogState Ltd represents a set of core values and a corporate philosophy that drive its operations. The company is committed to innovation, delivering cutting-edge solutions in the fields of cognitive assessment and clinical trials. CogState prioritizes integrity, ensuring transparent and ethical practices in all aspects of its business. With a focus on collaboration, CogState fosters strong partnerships to drive mutual success. The company values dedication to excellence, constantly striving for improvement and delivering high-quality products and services. CogState fosters a customer-centric approach, prioritizing customer satisfaction and delivering tailored solutions. Overall, CogState Ltd embodies a commitment to innovation, integrity, collaboration, excellence, and customer-centricity in its corporate philosophy.

Analysts currently set an average price target of 2,16 USD for the CogState stock (median: 2,16 USD), implying +9,6 % versus the latest price. The consensus is based on 6 analyst ratings.

CogState Analytikerens Kursmål 2026

7 analysts currently rate the CogState stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect CogState to generate revenue of 128,65 Mio. USD and earnings per share of 0,09 USD.

CogState Analytikerens Kursmål 2026

Converted at the current exchange rate, the CogState share trades at 1,71 EUR (1,97 USD).

The CogState share (CGS.AX) is listed on 2 stock exchanges, including: ASX (CGS.AX).

CogState Ltd is an innovative company specializing in the development and marketing of cognitive testing solutions. The company offers a wide range of products and services that can be used in the fields of pharmaceutical research, clinical diagnostics, and sports performance optimization. The three main business divisions of CogState Ltd include research and development of cognitive tests, clinical diagnostics and monitoring of patients with neurodegenerative disorders, and solutions for improving sports performance. The company's products are rooted in today's technology, as they are exclusively offered online. They allow for remote diagnosis and supervision of patients, saving time for therapists and improving diagnostic accuracy. The company's proprietary software platform enables researchers to effectively manage their studies and present study results in a concise format. CogState Ltd has a strategy in place to continue offering unique and expanding product offerings, allowing the company to remain a strong competitor in the industry.

forventet-omsætningen for CogState er 128,65 Mio. USD. Dette tal er baseret på aktuelle finansielle data og afspejler virksomhedens forretningsydeevne.

forventet-overskuddet for CogState er 16,22 Mio. USD. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.

Pris-til-indtjening-forholdet (P/E) for CogState er i øjeblikket 21,14. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af CogState-aktien.

Pris-til-salgs-forholdet (P/S) for CogState er i øjeblikket 2,67. P/S-forholdet sammenligner markedskapitalisering med årlig omsætning og fungerer som en værdiansættelsesmetrik for CogState-aktien.

AlleAktien-kvalitetsscore for CogState er 6/10.

ISIN for CogState er AU000000CGS8. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.

Tickeren for CogState er CGS.AX. Tickersymbolet bruges til at handle CogState-aktier på børsen.

I løbet af de seneste 12 måneder udbetalte CogState en dividende på 0,03 USD . Dette svarer til et dividendeafkast på ca. 1,45 %. For de kommende 12 måneder forventes CogState at udbetale en dividende på 0,03 USD.

Dividendeudbytteprocenten for CogState er i øjeblikket 1,45 %.

CogState har udbetalt dividende hvert år i de seneste 1 år.

For de kommende 12 måneder forventes dividender på 0,03 USD. Dette svarer til et dividendeafkast på 1,45 %.

CogState er klassificeret i sektoren 'Sundhed'.

For at modtage den seneste dividende fra CogState fra på 0,03 USD, skulle du have aktien i din portefølje før ex-datoen den .

Sidste dividende blev udbetalt den .

Dividenderne fra CogState udloddes i USD.